Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on PD-L1 expression by tumor cells and/or tumor mutational burden. However, mutations in oncogenic drivers such as EGFR, ALK, BR...

Descripción completa

Detalles Bibliográficos
Autores principales: Dantoing, Edouard, Piton, Nicolas, Salaün, Mathieu, Thiberville, Luc, Guisier, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230861/
https://www.ncbi.nlm.nih.gov/pubmed/34208111
http://dx.doi.org/10.3390/ijms22126288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230861/
https://www.ncbi.nlm.nih.gov/pubmed/34208111
http://dx.doi.org/10.3390/ijms22126288

Ejemplares similares